The Impact of Molecular Subtype on Efficacy of Chemotherapy and Checkpoint Inhibition in Advanced Gastric Cancer.
Yohei KubotaAkihito KawazoeAkinori SasakiSaori MishimaKentaro SawadaYoshiaki NakamuraDaisuke KotaniYasutoshi KubokiHiroya TaniguchiTakashi KojimaToshihiko DoiTakayuki YoshinoGenichiro IshiiTakeshi KuwataKohei ShitaraPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
MMR-D might result in shorter PFS with first-line chemotherapy for AGC. Subsequent anti-PD-1 therapy achieved higher ORR and longer PFS than prior chemotherapy in most patients with MMR-D, supporting the earlier use of immune checkpoint inhibitors.